474 related articles for article (PubMed ID: 26037126)
1. Inhibiting the Mammalian target of rapamycin blocks the development of experimental cerebral malaria.
Gordon EB; Hart GT; Tran TM; Waisberg M; Akkaya M; Skinner J; Zinöcker S; Pena M; Yazew T; Qi CF; Miller LH; Pierce SK
mBio; 2015 Jun; 6(3):e00725. PubMed ID: 26037126
[TBL] [Abstract][Full Text] [Related]
2. Activated Neutrophils Are Associated with Pediatric Cerebral Malaria Vasculopathy in Malawian Children.
Feintuch CM; Saidi A; Seydel K; Chen G; Goldman-Yassen A; Mita-Mendoza NK; Kim RS; Frenette PS; Taylor T; Daily JP
mBio; 2016 Feb; 7(1):e01300-15. PubMed ID: 26884431
[TBL] [Abstract][Full Text] [Related]
3. A single rapamycin dose protects against late-stage experimental cerebral malaria via modulation of host immunity, endothelial activation and parasite sequestration.
Mejia P; Treviño-Villarreal JH; Reynolds JS; De Niz M; Thompson A; Marti M; Mitchell JR
Malar J; 2017 Nov; 16(1):455. PubMed ID: 29121917
[TBL] [Abstract][Full Text] [Related]
4. Targeting the master regulator mTOR: a new approach to prevent the neurological of consequences of parasitic infections?
Donnelly S; Huston WM; Johnson M; Tiberti N; Saunders B; O'Brien B; Burke C; Labbate M; Combes V
Parasit Vectors; 2017 Nov; 10(1):581. PubMed ID: 29162126
[TBL] [Abstract][Full Text] [Related]
5. Targeting glutamine metabolism rescues mice from late-stage cerebral malaria.
Gordon EB; Hart GT; Tran TM; Waisberg M; Akkaya M; Kim AS; Hamilton SE; Pena M; Yazew T; Qi CF; Lee CF; Lo YC; Miller LH; Powell JD; Pierce SK
Proc Natl Acad Sci U S A; 2015 Oct; 112(42):13075-80. PubMed ID: 26438846
[TBL] [Abstract][Full Text] [Related]
6. Additive Therapy of Plasmodium berghei-Induced Experimental Cerebral Malaria via Dihydroartemisinin Combined with Rapamycin and Atorvastatin.
Song X; Cheng W; Zhu H; Li Y; Li J
Microbiol Spectr; 2023 Mar; 11(2):e0231722. PubMed ID: 36946739
[TBL] [Abstract][Full Text] [Related]
7. Cerebral malaria pathogenesis: Dissecting the role of CD4
Sharma I; Kataria P; Das J
Int Rev Immunol; 2024 Apr; ():1-18. PubMed ID: 38618863
[TBL] [Abstract][Full Text] [Related]
8. Proteomic profiling of the brain of mice with experimental cerebral malaria.
Moussa E; Huang H; Ahras M; Lall A; Thezenas ML; Fischer R; Kessler BM; Pain A; Billker O; Casals-Pascual C
J Proteomics; 2018 May; 180():61-69. PubMed ID: 28602553
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a murine model of cerebral malaria in KunMing mice infected with Plasmodium berghei ANKA.
Ding Y; Xu W; Zhou T; Liu T; Zheng H; Fu Y
Parasitology; 2016 Oct; 143(12):1672-80. PubMed ID: 27574013
[TBL] [Abstract][Full Text] [Related]
10. Human ApoE2 protects mice against
Liang R; Rao H; Pang Q; Xu R; Jiao Z; Lin L; Li L; Zhong L; Zhang Y; Guo Y; Xiao N; Liu S; Chen X-F; Su X-z; Li J
mBio; 2023 Oct; 14(6):e0234623. PubMed ID: 37874152
[TBL] [Abstract][Full Text] [Related]
11. CD8+ T Cells Induce Fatal Brainstem Pathology during Cerebral Malaria via Luminal Antigen-Specific Engagement of Brain Vasculature.
Swanson PA; Hart GT; Russo MV; Nayak D; Yazew T; Peña M; Khan SM; Janse CJ; Pierce SK; McGavern DB
PLoS Pathog; 2016 Dec; 12(12):e1006022. PubMed ID: 27907215
[TBL] [Abstract][Full Text] [Related]
12. MRI demonstrates glutamine antagonist-mediated reversal of cerebral malaria pathology in mice.
Riggle BA; Sinharay S; Schreiber-Stainthorp W; Munasinghe JP; Maric D; Prchalova E; Slusher BS; Powell JD; Miller LH; Pierce SK; Hammoud DA
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):E12024-E12033. PubMed ID: 30514812
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterium tuberculosis Coinfection Has No Impact on Plasmodium berghei ANKA-Induced Experimental Cerebral Malaria in C57BL/6 Mice.
Blank J; Behrends J; Jacobs T; Schneider BE
Infect Immun; 2016 Feb; 84(2):502-10. PubMed ID: 26644378
[TBL] [Abstract][Full Text] [Related]
14. Desperately Seeking Therapies for Cerebral Malaria.
Riggle BA; Miller LH; Pierce SK
J Immunol; 2020 Jan; 204(2):327-334. PubMed ID: 31907275
[TBL] [Abstract][Full Text] [Related]
15. Dietary restriction protects against experimental cerebral malaria via leptin modulation and T-cell mTORC1 suppression.
Mejia P; Treviño-Villarreal JH; Hine C; Harputlugil E; Lang S; Calay E; Rogers R; Wirth D; Duraisingh MT; Mitchell JR
Nat Commun; 2015 Jan; 6():6050. PubMed ID: 25636003
[TBL] [Abstract][Full Text] [Related]
16. CD47 blockade reduces the pathologic features of experimental cerebral malaria and promotes survival of hosts with
Torrez Dulgeroff LB; Oakley MS; Tal MC; Yiu YY; He JQ; Shoham M; Majam V; Okoth WA; Malla P; Kumar S; Weissman IL
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836556
[TBL] [Abstract][Full Text] [Related]
17. Perillyl alcohol exhibits in vitro inhibitory activity against Plasmodium falciparum and protects against experimental cerebral malaria.
Rodriguez AAM; Carvalho LJM; Kimura EA; Katzin AM
Int J Antimicrob Agents; 2018 Mar; 51(3):370-377. PubMed ID: 28843818
[TBL] [Abstract][Full Text] [Related]
18. Disruption of Parasite hmgb2 Gene Attenuates Plasmodium berghei ANKA Pathogenicity.
Briquet S; Lawson-Hogban N; Boisson B; Soares MP; Péronet R; Smith L; Ménard R; Huerre M; Mécheri S; Vaquero C
Infect Immun; 2015 Jul; 83(7):2771-84. PubMed ID: 25916985
[TBL] [Abstract][Full Text] [Related]
19. Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria.
Brooks HM; Hawkes MT
Curr Clin Pharmacol; 2017; 12(2):62-72. PubMed ID: 28676008
[TBL] [Abstract][Full Text] [Related]
20. Dimethyl fumarate reduces TNF and Plasmodium falciparum induced brain endothelium activation in vitro.
Mita-Mendoza NK; Magallon-Tejada A; Parmar P; Furtado R; Aldrich M; Saidi A; Taylor T; Smith J; Seydel K; Daily JP
Malar J; 2020 Oct; 19(1):376. PubMed ID: 33087130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
